Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Britta, Kaminsky"'
Autor:
Lucia Nogova, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Martin L. Sos, Sebastian Michels, Rieke N. Fischer, Meike Limburg, Diana S.Y. Abdulla, Thorsten Persigehl, Carsten Kobe, Sabine Merkelbach‐Bruse, Jeremy Franklin, Heiko Backes, Roland Schnell, Dirk Behringer, Britta Kaminsky, Martina Eichstaedt, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Yingying Tian, Lisa Junge, Ahmed A. Suleiman, Sebastian Frechen, Dennis Rokitta, Dongsheng Ouyang, Uwe Fuhr, Reinhard Buettner, Jürgen Wolf
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 4991-5007 (2020)
Abstract Background Treatment of patients with solid tumors and KRAS mutations remains disappointing. One option is the combined inhibition of pathways involved in RAF‐MEK‐ERK and PI3K‐AKT‐mTOR. Methods Patients with relapsed solid tumors wer
Externí odkaz:
https://doaj.org/article/04f6918ff70742839866e3f4fa056a57
Autor:
Jürgen Wolf, Reinhard Büttner, Mathieu Clement-Ziza, Lukas C. Heukamp, Britta Kaminsky, Thomas Geist, Ulrich Gerigk, Yon-Dschun Ko, Monika Serke, Carina Heydt, Jana Fassunke, Anna Eisert, Rieke Fischer, Sebastian Michels, Katharina König, Frank Ueckeroth, Michael Rauer, Anna Kron, Michaela A. Ihle, Sabine Merkelbach-Bruse, Matthias Scheffler, Rieke Frank
Purpose: KEAP1 and NFE2L2 mutations are associated with impaired prognosis in a variety of cancers and with squamous cell carcinoma formation in non–small cell lung cancer (NSCLC). However, little is known about frequency, histology dependence, mol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::438570b1ec0685eb9b4c9f90d1ab3452
https://doi.org/10.1158/1078-0432.c.6527654.v1
https://doi.org/10.1158/1078-0432.c.6527654.v1
Autor:
Jürgen Wolf, Reinhard Büttner, Mathieu Clement-Ziza, Lukas C. Heukamp, Britta Kaminsky, Thomas Geist, Ulrich Gerigk, Yon-Dschun Ko, Monika Serke, Carina Heydt, Jana Fassunke, Anna Eisert, Rieke Fischer, Sebastian Michels, Katharina König, Frank Ueckeroth, Michael Rauer, Anna Kron, Michaela A. Ihle, Sabine Merkelbach-Bruse, Matthias Scheffler, Rieke Frank
Supplemental Table 1-7 Supplemental Table 1: Diagnostic panels used for Next-generation sequencing (NGS) Supplemental Table 2: KEAP1 mutations Supplemental Table 3: NFE2L2 mutations Supplemental Table 4: Co-aberrations of KEAP1 Supplemental Table 5:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26f036f5e01c6e1155e337dc9abeb9da
https://doi.org/10.1158/1078-0432.22470680
https://doi.org/10.1158/1078-0432.22470680
Autor:
Jürgen Wolf, Reinhard Büttner, Mathieu Clement-Ziza, Lukas C. Heukamp, Britta Kaminsky, Thomas Geist, Ulrich Gerigk, Yon-Dschun Ko, Monika Serke, Carina Heydt, Jana Fassunke, Anna Eisert, Rieke Fischer, Sebastian Michels, Katharina König, Frank Ueckeroth, Michael Rauer, Anna Kron, Michaela A. Ihle, Sabine Merkelbach-Bruse, Matthias Scheffler, Rieke Frank
Main characteristics of the control group.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90f2126ee0c9e620a395f2041814bcda
https://doi.org/10.1158/1078-0432.22470677.v1
https://doi.org/10.1158/1078-0432.22470677.v1
Autor:
Dennis Rokitta, Max Taubert, Britta Kaminsky, Martin L. Sos, Reinhard Buettner, Carsten Kobe, Diana S.Y. Abdulla, Christian Mattonet, Lucia Nogova, Martina Eichstaedt, Dirk Behringer, Sabine Merkelbach-Bruse, Sebastian Michels, Dongsheng Ouyang, Lisa Junge, Meike Limburg, Sebastian Frechen, Masyar Gardizi, Jürgen Wolf, Jeremy Franklin, Matthias Scheffler, Uwe Fuhr, Heiko Backes, Rieke Fischer, Thorsten Persigehl, Yingying Tian, Roland Schnell, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Ahmed Abbas Suleiman
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 14, Pp 4991-5007 (2020)
Cancer Medicine, Vol 9, Iss 14, Pp 4991-5007 (2020)
Background Treatment of patients with solid tumors and KRAS mutations remains disappointing. One option is the combined inhibition of pathways involved in RAF‐MEK‐ERK and PI3K‐AKT‐mTOR. Methods Patients with relapsed solid tumors were treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6710a42760e313f5ebb3ac2205261983
https://doi.org/10.1002/cam4.3131
https://doi.org/10.1002/cam4.3131
Autor:
Jan Braess, Frank Ueckeroth, Diana S.Y. Abdulla, Carina Heydt, Anna-Kristina Eisert, Frank Beckers, Wolfram Meister, Hans-Joachim Kabitz, Johann Lorenzen, Monika Serke, Sabine Merkelbach-Bruse, Sebastian Michels, Jana Fassunke, Florian Kron, A. Meyer, Gabriele Wessling, Lucia Nogova, Bernhard Schaaf, Juliane Sueptitz, Matthias Scheffler, Carsten Schaepers, Sophia Koleczko, Reinhard Buettner, Clemens Schulte, Britta Kaminsky, Richard F. Riedel, Anna Kron, Stefan Krueger, Wolfgang Schulte, Joachim Lorenz, Michael Hamm, Kato Kambartel, Anne M. Schultheis, Christian Grohé, Jürgen Wolf, Lea Ruge, Jutta Kappes, Jens Panse, Niels Reinmuth, Rieke Fischer
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(4)
Robust data on the outcome of MET-aberrant NSCLC with nontargeted therapies are limited, especially in consideration of the heterogeneity of MET-amplified tumors (METamp).A total of 337 tumor specimens of patients with MET-altered Union for Internati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc23f7e85f05f773a1ed2d4bef0e7c16
https://pubmed.ncbi.nlm.nih.gov/33781436
https://pubmed.ncbi.nlm.nih.gov/33781436
Autor:
Winfried Randerath, Jens Kern, Jana Fassunke, Sabine Merkelbach-Bruse, Sebastian Michels, Cornelia von Levetzow, Matthias Scheffler, Anna Kron, Jürgen Wolf, Reinhard Büttner, Rieke Fischer, Alessandra Holzem, Karl-Otto Kambartel, Claudia Wompner, Britta Kaminsky, Theresa Westphal, Lucia Nogova, Jan-Philipp Weber, Richard F. Riedel, Diana S.Y. Abdulla, Elisabeth Bitter, Michaela Angelika Ihle, Sophia Koleczko, Ulrich Gerigk
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 144
Background MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive from known driver mutations. Activation of the MEK1-cascade is considered pivotal in resistance to targeted therapy approaches, and MAP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a076f188544b28df91c4987d96ec8628
https://pubmed.ncbi.nlm.nih.gov/32361034
https://pubmed.ncbi.nlm.nih.gov/32361034
Autor:
Britta Kaminsky, Reinhard Büttner, Frank Ueckeroth, Anna Eisert, Jana Fassunke, Ulrich Gerigk, Carina Heydt, Yon-Dschun Ko, Mathieu Clément-Ziza, Lukas C. Heukamp, Thomas Geist, Jürgen Wolf, Matthias Scheffler, Katharina König, Anna Kron, Sabine Merkelbach-Bruse, Sebastian Michels, Monika Serke, Michaela Angelika Ihle, Rieke Frank, Michael Rauer, Rieke Fischer
Publikováno v:
Clinical Cancer Research. 24:3087-3096
Purpose: KEAP1 and NFE2L2 mutations are associated with impaired prognosis in a variety of cancers and with squamous cell carcinoma formation in non–small cell lung cancer (NSCLC). However, little is known about frequency, histology dependence, mol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0be8a3e9db755535fe7f94c4f93fa9e6
https://doi.org/10.1158/1078-0432.ccr-17-3416
https://doi.org/10.1158/1078-0432.ccr-17-3416
Autor:
Theresa Westphal, Matthias Scheffler, Juergen Wolf, Jan-Phillip Weber, Martin Buchenroth, Rieke Fischer, Reinhard Buettner, Abdel Hakim Bayarassou, Sophia Koleczko, Diana Schaufler, Britta Kaminsky, Sabine Merkelbach-Bruse, Sebastian Michels, Anna Kron, Lucia Nogova, Clemens Schulte, R. Riedel, Christian Grohé, Axel M. Hillmer
Publikováno v:
Journal of Clinical Oncology. 39:e21098-e21098
e21098 Background: KEAP1 mutations have been shown to decrease the efficacy of both chemotherapy (CTX) and immune-checkpoint inhibition (ICI) in lung adenocarcinoma. However, few is known about their impact on systemic treatment of squamous cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44e82f22f1992a4a664c1a32c717c2ac
https://doi.org/10.1200/jco.2021.39.15_suppl.e21098
https://doi.org/10.1200/jco.2021.39.15_suppl.e21098
Autor:
Stefan Krüger, Juergen Wolf, Thomas Zander, Carina Heydt, Florian Kron, D. Koschel, Anne M. Schultheis, Anna Kron, R. Riedel, Monika Serke, Roman K. Thomas, Britta Kaminsky, Kato Kambartel, Danila Seidel, J. Benedikter, Matthias Scheffler, Jana Fassunke, Michaela Angelika Ihle, C. Alidousty, Christian Grohé, J. Braess, Sabine Merkelbach-Bruse, Sebastian Michels, Reinhard Büttner, Bernhard Schaaf, Lucia Nogova, Frank Ueckeroth, Martin Sebastian
Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). Patients and methods: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98d868b84ef1545219137cb6585f61c0
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/53566
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/53566